IASLC-WCLC 2019 - IASLC 20th World Conference on Lung Cancer
Sep 07 - Sep 10, 2019 | BarcelonaSpain
LARVOL is not affiliated with IASLC 20th World Conference on Lung Cancer and all trademarks, logos, and brand names are property of their respective owners
Showing 285 abstracts linked to Trials
Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia
Factors Associated with Prolonged Postoperative Hospital Stay in Patients Undergoing Lung Cancer Surgery
Best Management of Early Stage NSCLC in ILD Patients
Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial)
Predictive Value of EBUS Strain Elastography in Mediastinal Lymph Node Staging; The E-Predict Multicenter Study Results
Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRAS G12C Inhibitor, Evaluated in NSCLC
The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study
Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial
Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
In Vivo, Ex Vivo and Early Clinical Activity of EGFR Monoclonal Antibody and Osimertinib in EGFR Exon 20 Insertion NSCLC